Subscribe

Becton, Dickinson and Company (BDX)

USD153.83 +1.89 (+1.24%)
US NYSE S&P 500 Healthcare Medical - Instruments & Supplies
Address 1 Becton Drive 07417-1880
Franklin Lakes, NJ, US
CEO Thomas E. Polen Jr.
Website bd.com
IPO 1973-02-21
CIK 10795 ISIN US0758871091

Explore sections of this company profile

Also trades on London Stock Exchange · 0R19.L (USD) New York Stock Exchange · BDX (USD) New York Stock Exchange · BDXA (USD) New York Stock Exchange · BDXB (USD) Swiss Exchange · BDX.SW (CHF)
Description

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
BD BCR 2017-05-23 View
Bard 2018-03-08 View

Index membership

IndexAddedRemovedStatus
S&P 500 1972-09-14 Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD153.83 +1.89 (+1.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.28
Float Shares
361.62M
Free Float %
99.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.20% -5.20% -7.18% -19.49% -5.22% -6.17% +3.84% -27.89% -22.76% +11.66% +519.16%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (34 ratings, all time) Hold
Price Targets & DCF
Current price
153.83
Low 159.00 +3.4%
Consensus 173.19 +12.6%
Median 168.01 +9.2%
High 204.00 +32.6%
DCF (Unlevered) 1,493.25 +870.7%
DCF (Levered) 1,130.78 +635.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 44% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 6 +1
Hold 9 -1
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month 3
167.00
+8.6%
Last Quarter 6
174.17
+13.2%
Last Year 10
170.54
+10.9%
All Time 31
203.39
+32.2%
Quality scores
Altman Z-Score
2.20
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
2 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Instruments & Supplies: +7.9%
    +8.2% Q1'26: -10.6% (vs Q1'25)
  • EPS growth Medical - Instruments & Supplies: +16.3%
    -0.5% Q1'26: -203.7% (vs Q1'25)
  • FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +11.8% Q1'26: +11.6% (vs Q1'25)
  • EBIT margin Medical - Instruments & Supplies: +13.5%
    +11.4% Q1'26: +4.0% (vs Q1'25)
  • ROIC Medical - Instruments & Supplies: +6.0%
    +5.1% Q1'26: +1.1% (vs Q1'25)
  • Share dilution Medical - Instruments & Supplies: +0.1%
    -1.3% Q1'26: -3.0% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    3.87× Q1'26: 22.86× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.29) × ERP
WACC = 70% × Ke + 30% × Kd (4.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Intrinsic value (base): 1,407.57 Current price: 153.83
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Sep 2011
actual
Sep 2012
actual
Sep 2013
actual
Sep 2014
actual
Sep 2015
actual
Sep 2016
actual
Sep 2017
actual
Sep 2018
actual
Sep 2019
actual
Sep 2020
actual
Sep 2021
actual
Sep 2022
actual
Sep 2023
actual
Sep 2024
actual
Sep 2025
actual
Sep 2026
9 Rev. Ana.
8 EPS Ana.
Sep 2027
9 Rev. Ana.
8 EPS Ana.
Sep 2028
9 Rev. Ana.
1 EPS Ana.
Sep 2029
7 Rev. Ana.
1 EPS Ana.
Sep 2030
8 Rev. Ana.
1 EPS Ana.
Revenue
7.58B
est: 7.36B (+3.0%)
7.71B
est: 7.61B (+1.3%)
8.05B
est: 7.82B (+3.0%)
8.45B
est: 8.26B (+2.3%)
10.28B
est: 10.27B (+0.2%)
12.48B
est: 12.49B (-0.1%)
12.09B
est: 12.07B (+0.2%)
15.98B
est: 15.95B (+0.2%)
17.29B
est: 17.27B (+0.1%)
16.07B
est: 16.82B (-4.4%)
19.13B
est: 20.02B (-4.4%)
18.87B
est: 18.82B (+0.3%)
19.37B
est: 19.49B (-0.6%)
20.18B
est: 20.17B (+0.0%)
21.84B
est: 21.86B (-0.1%)
19.20B
19.16B – 19.24B
-12.2% YoY
19.67B
19.47B – 20.14B
+2.5% YoY
20.37B
20.31B – 20.44B
+3.6% YoY
21.09B
20.93B – 21.38B
+3.5% YoY
21.88B
21.70B – 22.17B
+3.7% YoY
EBITDA
2.20B
est: 2.18B (+0.6%)
2.12B
est: 2.49B (-14.8%)
1.85B
est: 1.78B (+3.7%)
2.22B
est: 2.13B (+4.3%)
2.00B
est: 2.07B (-3.1%)
2.58B
est: 2.75B (-6.2%)
2.59B
est: 2.04B (+26.5%)
3.86B
est: 4.68B (-17.6%)
4.07B
est: 3.66B (+11.3%)
3.06B
est: 3.44B (-11.2%)
4.39B
est: 3.91B (+12.3%)
4.41B
est: 4.19B (+5.4%)
4.40B
est: 4.60B (-4.4%)
4.82B
est: 4.66B (+3.3%)
4.96B
est: 5.05B (-1.9%)
4.44B
4.43B – 4.45B
-12.2% YoY
4.55B
4.50B – 4.66B
+2.5% YoY
4.71B
4.70B – 4.73B
+3.6% YoY
4.88B
4.84B – 4.94B
+3.5% YoY
5.06B
5.02B – 5.13B
+3.7% YoY
EBIT
1.70B
est: 1.64B (+3.6%)
1.61B
est: 1.60B (+0.5%)
1.30B
est: 1.19B (+9.7%)
1.66B
est: 1.54B (+7.9%)
1.11B
est: 1.03B (+7.8%)
1.46B
est: 1.73B (-15.7%)
1.50B
est: 871.54M (+71.8%)
1.88B
est: 2.11B (-11.1%)
1.82B
est: 1.36B (+33.1%)
942.00M
est: 1.62B (-42.0%)
2.16B
est: 2.02B (+6.9%)
2.18B
est: 2.27B (-3.9%)
2.11B
est: 2.50B (-15.3%)
2.53B
est: 2.33B (+8.7%)
2.50B
est: 2.52B (-1.2%)
2.22B
2.21B – 2.22B
-12.2% YoY
2.27B
2.25B – 2.33B
+2.5% YoY
2.35B
2.35B – 2.36B
+3.6% YoY
2.44B
2.42B – 2.47B
+3.5% YoY
2.53B
2.51B – 2.56B
+3.7% YoY
Net Income
1.27B
est: 1.17B (+8.6%)
1.17B
est: 1.47B (-20.7%)
1.29B
est: 898.63M (+43.9%)
1.19B
est: 1.12B (+5.8%)
695.00M
est: 656.73M (+5.8%)
976.00M
est: 1.20B (-18.6%)
1.10B
est: 393.09M (+179.8%)
311.00M
est: 1.02B (-69.4%)
1.23B
est: 903.88M (+36.4%)
874.00M
est: 1.14B (-23.0%)
2.09B
est: 1.49B (+40.7%)
1.78B
est: 1.60B (+11.1%)
1.48B
est: 1.27B (+17.3%)
1.71B
est: 2.96B (-42.3%)
1.68B
est: 3.25B (-48.3%)
3.62B
3.53B – 3.71B
+11.5% YoY
4.05B
3.65B – 4.45B
+11.9% YoY
4.14B
4.08B – 4.19B
+2.1% YoY
4.38B
4.33B – 4.45B
+5.8% YoY
4.74B
4.69B – 4.82B
+8.3% YoY
SGA
1.82B
est: 1.82B (+0.1%)
1.92B
est: 1.90B (+1.4%)
2.42B
est: 2.34B (+3.3%)
2.15B
est: 2.10B (+2.3%)
2.56B
est: 2.66B (-3.6%)
3.01B
est: 2.77B (+8.4%)
2.91B
est: 2.93B (-0.7%)
4.02B
est: 4.25B (-5.5%)
4.33B
est: 4.36B (-0.5%)
4.19B
est: 5.50B (-23.9%)
4.72B
est: 4.32B (+9.3%)
4.71B
est: 4.57B (+3.0%)
4.72B
est: 5.03B (-6.2%)
4.86B
est: 4.93B (-1.5%)
5.28B
est: 5.34B (-1.2%)
4.69B
4.68B – 4.70B
-12.2% YoY
4.81B
4.76B – 4.92B
+2.5% YoY
4.98B
4.96B – 5.00B
+3.6% YoY
5.16B
5.11B – 5.23B
+3.5% YoY
5.35B
5.30B – 5.42B
+3.7% YoY
EPS
5.75
est: 5.09 (+13.0%)
5.59
est: 5.43 (+2.9%)
6.63
est: 5.34 (+24.2%)
6.13
est: 6.08 (+0.8%)
3.43
est: 6.93 (-50.5%)
4.59
est: 8.36 (-45.1%)
4.70
est: 9.22 (-49.0%)
0.62
est: 10.72 (-94.2%)
3.96
est: 11.39 (-65.2%)
2.75
est: 9.68 (-71.6%)
6.92
est: 12.60 (-45.1%)
5.93
est: 11.33 (-47.7%)
4.97
est: 4.39 (+13.1%)
5.88
est: 10.30 (-42.9%)
5.84
est: 11.30 (-48.3%)
12.58
12.28 – 12.92
+11.4% YoY
13.45
12.71 – 15.50
+6.9% YoY
14.35
14.21 – 14.61
+6.7% YoY
15.25
15.09 – 15.51
+6.2% YoY
16.51
16.34 – 16.80
+8.3% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-05-04 TD Cowen Hold Hold Maintain
2026-04-17 Piper Sandler Neutral Neutral Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-07 B+ 3/5 5/5 2/5 4/5 2/5 2/5 4/5
2026-05-06 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-05 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-04 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-01 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-04-30 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-04-29 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-28 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-27 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-24 B+ 3/5 5/5 3/5 4/5 1/5 2/5 3/5
2026-04-23 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-22 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-21 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-20 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-17 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-16 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-15 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
3.31B
OE per share TTM
11.54
Owner's Yield
7.69%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
33.1%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
747
Total invested
4.56B
Insider transactions (90d)
1
Beneficial owners (>5%)
15
Beneficial owners (>5%)
# Reporting person Amount owned % of class Sole voting Shared voting Sole dispositive Shared dispositive Type Citizenship Filing date SEC filing
1 Ban Siong Ang 46.39M 77.00% IN MARYLAND 2015-02-12
2 FMR Corp. 25.55M 10.44% 1.33M 25.55M HC Delaware 2007-04-10
3 The Vanguard Group - 23-1945930 24.18M 8.48% 458.5K 23.02M 1.16M IA Pennsylvania For 2022-02-09
4 (1) BlackRock, Inc. 21.35M 7.50% 18.65M 21.35M HC Delaware 2022-02-08
5 52-0556948 20.02M 7.00% 7.78M 20.02M IA Maryland 2022-02-14
6 Edward C. Johnson 3d 18.92M 7.75% 18.92M IN United States of America 2008-07-10
7 STATE STREET CORPORATION 11.41M 4.97% 11.41M 11.41M HC BOSTON, MASSACHUSETTS 2018-02-13
8 943112180 7.61M 3.16% 5.97M 7.61M BK U.S.A. 2009-02-03
9 BARCLAYS GLOBAL FUND ADVISORS 2.03M 0.84% 2.01M 2.03M IA U.S.A. 2009-02-03
10 BARCLAYS GLOBAL INVESTORS, LTD 1.24M 0.51% 1.09M 1.24M FI England 2009-02-03
11 BARCLAYS GLOBAL INVESTORS JAPAN LIMITED 509.4K 0.21% 509.4K 509.4K FI Japan 2009-02-03
12 BARCLAYS GLOBAL INVESTORS CANADA LIMITED 176.9K 0.07% 176.9K 176.9K FI Canada 2009-02-03
13 BARCLAYS GLOBAL INVESTORS AUSTRALIA LIMITED 13.1K 0.01% 13.1K 13.1K FI Australia 2009-02-03
14 04-1867445 0.00% BK BOSTON, MASSACHUSETTS 2010-02-12
15 BARCLAYS GLOBAL INVESTORS (DEUTSCHLAND) AG 0.00% FI Germany 2009-02-03

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
747
-829 vs prev Q
New positions
52
Closed positions
850
Increased
345
Reduced
257
Put/Call ratio
0.00
Calls held
Puts held
Top institutional holders
# Investor Shares / Δ Mkt value / Δ Own% / Δ Weight% / Δ Avg px / Perf. Hold / Status
1 VANGUARD GROUP INC 36.68M +4.2M (+13.0%) 7.12B +1.0B (+17.2%) 16.37% +5.097 pp 0.10% +0.012 pp USD167.14 -8.7% 84 qtrs
2 BLACKROCK, INC. 27.65M -103.6K (-0.4%) 5.37B +171.4M (+3.3%) 12.34% +2.701 pp 0.09% 0.000 pp USD214.38 -28.8% 6 qtrs
3 T. ROWE PRICE INVESTMENT MANAGEMENT, INC. 14.38M -1.9M (-11.4%) 2.79B -247.9M (-8.2%) 6.42% +0.779 pp 1.76% -0.096 pp USD213.02 -28.4% 14 qtrs
4 STATE STREET CORP 13.99M +116.7K (+0.8%) 2.71B +118.4M (+4.6%) 6.24% +1.425 pp 0.09% +0.001 pp USD157.46 -3.1% 51 qtrs
5 FIRST EAGLE INVESTMENT MANAGEMENT, LLC 11.65M +1.7M (+16.5%) 2.26B +389.5M (+20.8%) 4.06% +0.593 pp 3.98% +0.572 pp USD206.28 -5.9% 21 qtrs
6 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 9.49M +336.1K (+3.7%) 1.84B +128.4M (+7.5%) 3.31% +0.133 pp 0.59% +0.063 pp USD224.54 -13.6% 28 qtrs
7 GEODE CAPITAL MANAGEMENT, LLC 6.89M +53.9K (+0.8%) 1.33B +57.8M (+4.5%) 3.07% +0.700 pp 0.08% +0.001 pp USD184.76 -17.4% 78 qtrs
8 WELLINGTON MANAGEMENT GROUP LLP 5.30M +66.9K (+1.3%) 1.03B +49.1M (+5.0%) 2.36% +0.548 pp 0.18% +0.009 pp USD179.81 -15.2% 81 qtrs
9 FRANKLIN RESOURCES INC 5.24M -1.5M (-22.2%) 1.02B -243.2M (-19.3%) 2.34% +0.001 pp 0.25% -0.065 pp USD168.07 -9.2% 51 qtrs
10 PRICE T ROWE ASSOCIATES INC /MD/ 4.28M -343.3K (-7.4%) 830.47M -34.7M (-4.0%) 1.91% +0.304 pp 0.09% -0.003 pp USD217.63 -29.9% 75 qtrs
11 CLEARBRIDGE INVESTMENTS, LLC 4.09M -314.7K (-7.1%) 794.20M -30.7M (-3.7%) 1.83% +0.296 pp 0.64% +0.015 pp USD211.43 -27.8% 62 qtrs
12 INVESCO LTD. 3.79M +1.2M (+48.5%) 735.62M +257.8M (+53.9%) 1.69% +0.805 pp 0.11% +0.038 pp USD187.93 -18.8% 57 qtrs
13 NORGES BANK 3.78M +3.8M (+100.0%) 734.32M +734.3M (+100.0%) 1.69% +1.688 pp 0.08% +0.079 pp USD152.56 +0.0% 1 qtrs NEW
14 JPMORGAN CHASE & CO 3.49M -1.8M (-33.9%) 678.01M -311.7M (-31.5%) 1.22% -0.617 pp 0.04% -0.017 pp USD212.17 -8.5% 51 qtrs
15 MORGAN STANLEY 3.37M -92.1K (-2.7%) 654.92M +6.0M (+0.9%) 1.51% +0.302 pp 0.04% 0.000 pp USD224.54 -32.1% 51 qtrs
16 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3.20M -102.6K (-3.1%) 620.91M +3.4M (+0.6%) 1.43% +0.281 pp 0.10% -0.002 pp USD206.08 -26.0% 93 qtrs
17 AMERICAN CENTURY COMPANIES INC 3.13M -123.9K (-3.8%) 607.37M -1.6M (-0.3%) 1.40% +0.267 pp 0.31% -0.005 pp USD212.74 -28.3% 51 qtrs
18 VERITAS ASSET MANAGEMENT LLP 2.87M -80.3K (-2.7%) 557.87M +4.8M (+0.9%) 1.28% +0.257 pp 5.71% -0.200 pp USD204.89 -25.5% 24 qtrs
19 HARRIS ASSOCIATES L P 2.84M -273.7K (-8.8%) 551.49M -31.6M (-5.4%) 1.27% +0.186 pp 0.70% -0.238 pp USD190.11 -19.8% 5 qtrs
20 BANK OF AMERICA CORP /DE/ 2.81M +114.1K (+4.2%) 545.98M +40.8M (+8.1%) 1.26% +0.318 pp 0.04% +0.005 pp USD208.82 -26.9% 52 qtrs
21 NORDEA INVESTMENT MANAGEMENT AB 2.77M -458.5K (-14.2%) 541.33M -51.6M (-8.7%) 0.97% -0.155 pp 0.46% -0.054 pp USD237.50 -18.3% 88 qtrs
22 NORTHERN TRUST CORP 2.50M -71.9K (-2.8%) 486.01M +3.8M (+0.8%) 1.12% +0.223 pp 0.06% +0.000 pp USD146.98 +3.8% 51 qtrs
23 DIMENSIONAL FUND ADVISORS LP 2.41M +63.5K (+2.7%) 466.86M +28.6M (+6.5%) 1.07% +0.260 pp 0.10% +0.004 pp USD200.71 -24.0% 51 qtrs
24 MANUFACTURERS LIFE INSURANCE COMPANY, THE 2.38M -193.4K (-7.5%) 462.90M -19.6M (-4.1%) 1.06% +0.169 pp 0.38% -0.016 pp USD187.04 -18.4% 108 qtrs
25 LONGVIEW PARTNERS (GUERNSEY) LTD 2.16M -110.9K (-4.9%) 419.31M -5.8M (-1.4%) 0.96% +0.175 pp 4.38% -0.065 pp USD215.19 -29.1% 20 qtrs
26 FIRST PACIFIC ADVISORS, LP 1.95M +1.0M (+108.4%) 378.68M +203.4M (+116.1%) 0.87% +0.546 pp 4.99% +2.563 pp USD165.62 -7.9% 2 qtrs
27 LEGAL & GENERAL GROUP PLC 1.93M +11.0K (+0.6%) 374.64M +15.4M (+4.3%) 0.86% +0.195 pp 0.08% +0.003 pp USD172.24 -11.4% 75 qtrs
28 BANK OF NEW YORK MELLON CORP 1.73M -24.3K (-1.4%) 335.25M +7.4M (+2.3%) 0.77% +0.163 pp 0.06% -0.004 pp USD192.06 -20.6% 66 qtrs
29 GOLDMAN SACHS GROUP INC 1.63M -216.6K (-11.8%) 315.78M -29.3M (-8.5%) 0.57% -0.073 pp 0.04% -0.004 pp USD208.60 -7.0% 73 qtrs
30 BARCLAYS PLC 1.60M +939.7K (+141.9%) 310.91M +151.2M (+94.7%) 0.71% +0.485 pp 0.07% +0.034 pp USD182.26 -16.3% 51 qtrs
31 FMR LLC 1.53M +528.2K (+52.6%) 297.51M +109.4M (+58.2%) 0.68% +0.335 pp 0.02% +0.005 pp USD189.09 -19.3% 70 qtrs
32 UBS ASSET MANAGEMENT AMERICAS INC 1.50M -19.6K (-1.3%) 290.46M +6.6M (+2.3%) 0.67% +0.141 pp 0.06% 0.000 pp USD183.17 -16.7% 90 qtrs
33 MARSHALL WACE, LLP 1.46M +1.5M (+44,008.7%) 282.74M +282.1M (+45,634.8%) 0.65% +0.649 pp 0.26% +0.257 pp USD152.62 0.0% 13 qtrs
34 SOUTHPOINT CAPITAL ADVISORS LP 1.40M +— (+0.0%) 271.70M +9.7M (+3.7%) 0.62% +0.139 pp 6.32% -0.557 pp USD188.02 -18.9% 4 qtrs
35 AMERIPRISE FINANCIAL INC 1.39M +1.1M (+437.5%) 269.54M +221.1M (+457.0%) 0.62% +0.530 pp 0.06% +0.050 pp USD165.42 -7.8% 56 qtrs
36 1832 ASSET MANAGEMENT L.P. 1.37M +930.5K (+213.2%) 265.26M +183.6M (+224.8%) 0.61% +0.458 pp 0.20% +0.138 pp USD167.11 -8.7% 49 qtrs
37 AMUNDI 1.31M -527.4K (-28.7%) 254.45M -98.5M (-27.9%) 0.59% -0.053 pp 0.07% -0.044 pp USD230.36 -33.8% 19 qtrs
38 UBS GROUP AG 1.29M +156.7K (+13.8%) 251.00M +38.2M (+18.0%) 0.58% +0.182 pp 0.04% +0.007 pp USD195.03 -21.8% 45 qtrs
39 WELLS FARGO & COMPANY/MN 1.25M -184.0K (-12.8%) 243.03M -25.8M (-9.6%) 0.56% +0.060 pp 0.04% -0.007 pp USD138.67 +10.0% 57 qtrs
40 BRANDES INVESTMENT PARTNERS, LP 1.23M +77.1K (+6.7%) 238.65M +22.9M (+10.6%) 0.55% +0.149 pp 1.82% +0.086 pp USD169.75 -10.1% 3 qtrs
41 AQR CAPITAL MANAGEMENT LLC 1.19M +153.1K (+14.8%) 230.35M +39.7M (+20.8%) 0.53% +0.171 pp 0.12% -0.001 pp USD175.71 -13.2% 87 qtrs
42 HOLOCENE ADVISORS, LP 1.17M +1.2M (+100.0%) 226.24M +226.2M (+100.0%) 0.52% +0.520 pp 0.48% +0.475 pp USD152.56 +0.0% 14 qtrs
43 COOKE & BIELER LP 1.13M +240.7K (+27.2%) 218.61M +52.8M (+31.9%) 0.50% +0.195 pp 2.28% +0.568 pp USD200.44 -23.9% 52 qtrs
44 FIDUCIARY MANAGEMENT INC /WI/ 1.10M -86.7K (-7.3%) 214.14M -8.6M (-3.9%) 0.49% +0.079 pp 2.35% +0.101 pp USD172.39 -11.5% 3 qtrs
45 LONGAEVA PARTNERS L.P. 1.00M +1.0M (+100.0%) 194.07M +194.1M (+100.0%) 0.45% +0.446 pp 16.28% +16.279 pp USD152.56 +0.0% 1 qtrs NEW
46 DEUTSCHE BANK AG\ 952.4K +201.3K (+26.8%) 184.84M +44.3M (+31.5%) 0.33% +0.072 pp 0.06% +0.013 pp USD216.62 -10.4% 50 qtrs
47 FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ 951.5K +45.7K (+5.0%) 184.65M +15.1M (+8.9%) 0.33% +0.018 pp 0.98% +0.065 pp USD230.19 -15.7% 8 qtrs
48 ENVESTNET ASSET MANAGEMENT INC 942.9K -132.7K (-12.3%) 182.98M -18.3M (-9.1%) 0.42% +0.047 pp 0.05% -0.004 pp USD224.06 -31.9% 51 qtrs
49 STARBOARD VALUE LP 929.9K -278.1K (-23.0%) 180.47M -45.6M (-20.2%) 0.41% -0.005 pp 3.42% -0.836 pp USD210.18 -27.4% 4 qtrs
50 M&G PLC 917.4K -18.1K (-1.9%) 177.97M +3.0M (+1.7%) 0.41% +0.085 pp 0.91% -0.016 pp USD193.09 -21.0% 8 qtrs
51 PROSHARE ADVISORS LLC 901.8K -69.5K (-7.2%) 175.01M -6.8M (-3.7%) 0.31% -0.023 pp 0.31% -0.072 pp USD214.96 -9.7% 76 qtrs
52 COLONY GROUP, LLC 884.1K +831.0K (+1,566.6%) 171.53M +161.6M (+1,635.7%) 0.39% +0.376 pp 0.20% +0.180 pp USD155.74 -2.0% 9 qtrs
53 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 839.9K +469.8K (+127.0%) 162.99M +93.7M (+135.4%) 0.37% +0.246 pp 0.10% +0.052 pp USD161.79 -5.7% 3 qtrs
54 SWISS NATIONAL BANK 785.5K -40.7K (-4.9%) 152.44M -2.2M (-1.4%) 0.35% +0.064 pp 0.09% +0.001 pp USD168.02 -9.2% 51 qtrs
55 RAYMOND JAMES FINANCIAL INC 765.4K -171.0K (-18.3%) 148.54M -26.7M (-15.2%) 0.34% +0.016 pp 0.05% -0.010 pp USD222.78 -31.5% 5 qtrs
56 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 735.9K -147.3K (-16.7%) 142.81M -22.5M (-13.6%) 0.33% +0.022 pp 0.08% -0.017 pp USD218.38 -30.1% 57 qtrs
57 CAISSE DE DEPOT ET PLACEMENT DU QUEBEC 730.6K +334.8K (+84.6%) 141.78M +67.7M (+91.4%) 0.33% +0.189 pp 0.24% +0.107 pp USD170.75 -10.7% 4 qtrs
58 SG AMERICAS SECURITIES, LLC 730.1K +491.3K (+205.7%) 141.68M +97.0M (+217.0%) 0.25% +0.172 pp 0.18% +0.030 pp USD189.34 +2.5% 51 qtrs
59 CULLEN CAPITAL MANAGEMENT, LLC 697.8K -18.5K (-2.6%) 135.42M +1.4M (+1.0%) 0.31% +0.063 pp 1.48% +0.012 pp USD174.29 -12.5% 3 qtrs
60 SUMITOMO MITSUI TRUST HOLDINGS, INC. 665.5K -30.5K (-4.4%) 129.15M -1.1M (-0.9%) 0.23% -0.010 pp 0.08% +0.001 pp USD158.28 +22.6% 59 qtrs
61 ROYAL BANK OF CANADA 644.1K -20.6K (-3.1%) 125.01M +595.0K (+0.5%) 0.29% +0.057 pp 0.02% 0.000 pp USD223.91 -31.9% 51 qtrs
62 NUVEEN, LLC 632.5K +27.9K (+4.6%) 122.74M +9.6M (+8.5%) 0.28% +0.072 pp 0.03% +0.002 pp USD210.05 -27.4% 4 qtrs
63 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 627.9K +26.7K (+4.4%) 122.40M +9.9M (+8.8%) 0.22% +0.010 pp 0.08% +0.002 pp USD227.12 -14.6% 58 qtrs
64 DAVENPORT & CO LLC 614.0K -30.7K (-4.8%) 119.45M -621.7K (-0.5%) 0.21% -0.010 pp 0.64% -0.004 pp USD218.15 -11.0% 51 qtrs
65 DEKABANK DEUTSCHE GIROZENTRALE 460.1K +— (+0.0%) 117.86M +33.6M (+39.9%) 0.21% +0.046 pp 0.20% +0.062 pp USD203.70 -25.1% 66 qtrs
66 NOMURA ASSET MANAGEMENT CO LTD 581.0K -16.1K (-2.7%) 112.76M +994.1K (+0.9%) 0.26% +0.052 pp 0.29% -0.006 pp USD217.54 -29.9% 76 qtrs
67 BRISTOL JOHN W & CO INC /NY/ 577.5K -11.9K (-2.0%) 112.08M +1.8M (+1.6%) 0.26% +0.053 pp 1.72% -0.018 pp USD157.70 -3.3% 80 qtrs
68 BNP PARIBAS ARBITRAGE, SNC 575.4K +269.8K (+88.3%) 111.66M +54.5M (+95.2%) 0.26% +0.151 pp 0.05% +0.020 pp USD179.35 -14.9% 51 qtrs
69 EVERETT HARRIS & CO /CA/ 550.9K +1.4K (+0.3%) 106.91M +4.1M (+4.0%) 0.25% +0.055 pp 1.29% +0.025 pp USD143.52 +6.3% 61 qtrs
70 LIONTRUST INVESTMENT PARTNERS LLP 547.1K -47.9K (-8.1%) 106.17M -5.2M (-4.7%) 0.24% +0.038 pp 1.58% +0.010 pp USD207.98 -26.6% 4 qtrs
71 NEW YORK STATE COMMON RETIREMENT FUND 545.5K -1.1K (-0.2%) 105.87M +3.6M (+3.5%) 0.24% +0.054 pp 0.14% +0.009 pp USD166.92 -8.6% 103 qtrs
72 MAWER INVESTMENT MANAGEMENT LTD. 543.1K -522.9K (-49.0%) 105.41M -94.1M (-47.2%) 0.24% -0.128 pp 0.59% -0.446 pp USD177.47 -14.0% 51 qtrs
73 BANK OF MONTREAL /CAN/ 536.2K +141.3K (+35.8%) 104.07M +30.1M (+40.8%) 0.24% +0.102 pp 0.04% +0.008 pp USD200.89 -24.1% 46 qtrs
74 CITADEL ADVISORS LLC 512.8K +154.2K (+43.0%) 99.52M +32.4M (+48.3%) 0.23% +0.104 pp 0.01% +0.005 pp USD195.35 -21.9% 52 qtrs
75 ABRDN PLC 511.5K -4.6K (-0.9%) 99.26M +4.3M (+4.5%) 0.18% -0.001 pp 0.15% +0.004 pp USD219.50 -11.6% 34 qtrs
76 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 508.2K +— (+0.0%) 98.64M +3.5M (+3.7%) 0.23% +0.050 pp 0.08% -0.002 pp USD163.73 -6.8% 91 qtrs
77 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 485.7K -10.9K (-2.2%) 94.26M +1.3M (+1.4%) 0.22% +0.044 pp 0.09% -0.001 pp USD147.07 +3.7% 52 qtrs
78 RHUMBLINE ADVISERS 470.7K -5.1K (-1.1%) 91.35M +2.3M (+2.6%) 0.21% +0.045 pp 0.07% +0.002 pp USD163.49 -6.7% 52 qtrs
79 NATIONAL PENSION SERVICE 463.0K +18.3K (+4.1%) 89.86M +6.6M (+8.0%) 0.21% +0.052 pp 0.07% +0.002 pp USD200.30 -23.8% 46 qtrs
80 RIVER ROAD ASSET MANAGEMENT, LLC 436.9K +45.9K (+11.7%) 84.78M +11.6M (+15.9%) 0.15% +0.017 pp 0.93% +0.110 pp USD200.41 -3.2% 5 qtrs
81 JANUS HENDERSON GROUP PLC 421.2K +7.7K (+1.9%) 81.75M +4.3M (+5.6%) 0.19% +0.044 pp 0.04% +0.001 pp USD182.92 -16.6% 87 qtrs
82 LAZARD FRERES GESTION S.A.S. 375.6K -86.2K (-18.7%) 72.88M -13.6M (-15.7%) 0.17% +0.007 pp 1.31% -0.332 pp USD238.36 -36.0% 21 qtrs
83 CITIGROUP INC 368.7K +9.1K (+2.5%) 71.55M +4.2M (+6.3%) 0.16% +0.040 pp 0.03% +0.002 pp USD212.32 -28.1% 108 qtrs
84 STIFEL FINANCIAL CORP 367.0K -60.1K (-14.1%) 71.23M -8.7M (-10.9%) 0.16% +0.016 pp 0.06% -0.009 pp USD211.00 -27.7% 48 qtrs
85 CLARKSTON CAPITAL PARTNERS, LLC 366.3K -10.6K (-2.8%) 71.08M +545.9K (+0.8%) 0.16% +0.033 pp 1.65% +0.126 pp USD181.34 -15.9% 5 qtrs
86 LPL FINANCIAL LLC 363.1K -33.3K (-8.4%) 70.46M -3.7M (-5.0%) 0.16% +0.024 pp 0.02% -0.002 pp USD219.02 -30.3% 51 qtrs
87 NATIXIS ADVISORS, L.P. 356.2K +48.7K (+15.8%) 69.14M +11.6M (+20.1%) 0.16% +0.052 pp 0.10% +0.014 pp USD194.15 -21.4% 38 qtrs
88 HSBC HOLDINGS PLC 350.0K +350.0K (+100.0%) 68.35M +68.4M (+100.0%) 0.12% +0.122 pp 0.03% +0.035 pp USD194.07 +0.0% 1 qtrs NEW
89 FREESTONE GROVE PARTNERS LP 335.4K +335.4K (+100.0%) 65.09M +65.1M (+100.0%) 0.15% +0.150 pp 0.47% +0.471 pp USD152.56 +0.0% 1 qtrs NEW
90 ALLIANCEBERNSTEIN L.P. 307.7K -506.0K (-62.2%) 59.72M -92.6M (-60.8%) 0.14% -0.145 pp 0.02% -0.029 pp USD222.04 -31.3% 61 qtrs
91 SUSQUEHANNA INTERNATIONAL GROUP, LLP 305.5K +112.7K (+58.5%) 59.29M +23.2M (+64.3%) 0.14% +0.069 pp 0.01% +0.003 pp USD179.29 -14.9% 51 qtrs
92 BALYASNY ASSET MANAGEMENT L.P. 283.6K +283.6K (+100.0%) 55.04M +55.0M (+100.0%) 0.13% +0.127 pp 0.07% +0.070 pp USD152.56 +0.0% 13 qtrs
93 FIRST TRUST ADVISORS LP 278.6K -18.1K (-6.1%) 54.07M -1.5M (-2.6%) 0.12% +0.021 pp 0.04% -0.002 pp USD221.88 -31.2% 51 qtrs
94 269.5K +269.5K (+100.0%) 52.30M +52.3M (+100.0%) 0.12% +0.120 pp 1.03% +1.027 pp USD152.56 +0.0% 1 qtrs NEW
95 TD ASSET MANAGEMENT INC 267.5K -11.2K (-4.0%) 51.91M -245.4K (-0.5%) 0.12% +0.023 pp 0.04% -0.001 pp USD199.84 -23.7% 51 qtrs
96 SEI INVESTMENTS CO 267.1K +78.9K (+41.9%) 51.83M +16.6M (+47.1%) 0.12% +0.054 pp 0.05% +0.013 pp USD197.79 -22.9% 45 qtrs
97 BELLEVUE GROUP AG 265.7K -31.2K (-10.5%) 51.56M -4.0M (-7.2%) 0.12% +0.015 pp 0.98% -0.178 pp USD227.46 -32.9% 40 qtrs
98 NEUBERGER BERMAN GROUP LLC 262.5K -10.1K (-3.7%) 50.98M +40.0K (+0.1%) 0.12% +0.023 pp 0.04% +0.001 pp USD228.63 -33.3% 57 qtrs
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
Shares disposed
1.2K
Cash buys
Cash sales
1.00
Net activity
-1,220
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-27 Feld Michael Officer S-Sale D Common Stock 74 151.94 11.2K 21,159 D
2026-04-06 Neal Shana Carol Officer F-InKind D Common Stock 1,146 0.00 23,966 D
2026-03-26 Feld Michael Officer S-Sale D Common Stock 75 156.83 11.8K 21,233 D
2026-03-16 Minnix Lanesha Officer A-Award A Common Stock 7,492 0.00 7,492 D
2026-03-02 Spikner Pamela L. Officer A-Award A Common Stock 931 0.00 3,323 D
2026-03-02 Roque Vitor Officer A-Award A Common Stock 931 0.00 6,510 D
2026-02-26 Feld Michael Officer S-Sale D Common Stock 75 181.84 13.6K 21,308 D
2026-02-18 SCOTT BERTRAM L Director S-Sale D Common Stock 953 182.61 174.0K 36,763 D
2026-02-04 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 272 0.00 11,649 D
2026-02-04 Huffines Robert Luther Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 100 0.00 100 D
2026-02-04 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 30 0.00 1,714 D
2026-02-01 Urbini Massimiliano Officer Common Stock 0 0.00 4,133 D
2026-01-27 Wright Jacqueline Director A-Award A Common Stock 1,098 0.00 1,279 D
2026-01-27 Waldstreicher Joanne Director A-Award A Common Stock 1,098 0.00 3,391 D
2026-01-27 SCOTT BERTRAM L Director A-Award A Common Stock 1,098 0.00 37,716 D
2026-01-27 RING TIMOTHY M Director A-Award A Common Stock 1,098 0.00 59,160 D
2026-01-27 Jones Christopher Ian Montague Director A-Award A Common Stock 1,098 0.00 24,304 D
2026-01-27 Huffines Robert Luther Director A-Award A Common Stock 1,098 0.00 1,279 D
2026-01-27 Henderson Jeffrey William Director A-Award A Common Stock 1,098 0.00 9,143 D
2026-01-27 HAYES GREGORY Director A-Award A Common Stock 1,098 0.00 7,159 D
2026-01-27 ECKERT R ANDREW Director A-Award A Common Stock 1,098 0.00 10,423 D
2026-01-27 Byington Carrie L Director A-Award A Common Stock 1,098 0.00 5,018 D
2026-01-27 Brown William M Director A-Award A Common Stock 1,098 0.00 4,663 D
2026-01-26 Feld Michael Officer S-Sale D Common Stock 75 202.73 15.2K 16,431 D
2026-01-21 Spikner Pamela L. Officer F-InKind D Common Stock 84 0.00 1,832 D
2026-01-15 Garrison Michael David Officer D-Return D Common Stock 2,454 209.00 512.9K 13,705 D
2026-01-03 Shan David Officer F-InKind D Common Stock 44 0.00 8,926 D
2025-12-26 Feld Michael Officer S-Sale D Common Stock 74 196.08 14.5K 16,506 D
2025-12-17 Garrison Michael David Officer S-Sale D Common Stock 629 196.03 123.3K 13,105 D
2025-12-05 Roque Vitor Officer Common Stock 0 0.00 4,477 D
2025-12-01 Wright Jacqueline Director No securities are beneficially owned 0 0.00 0 D
2025-12-01 Huffines Robert Luther Director A-Award A Common Stock 180 0.00 180 D
2025-12-01 Feld Michael Officer S-Sale D Common Stock 75 193.36 14.5K 16,580 D
2025-11-26 Urbini Massimiliano Officer Stock Appreciation Rights 1,984 224.25 444.9K 0 D
2025-11-26 Spikner Pamela L. Officer A-Award A Common Stock 1,234 0.00 1,916 D
2025-11-26 Shan David Officer A-Award A Common Stock 3,504 0.00 8,079 D
2025-11-26 Roque Vitor Officer Stock Appreciation Rights 1,849 224.25 414.6K 0 D
2025-11-26 Polen Thomas E Jr Officer A-Award A Stock Appreciation Rights 165,581 193.90 32.11M 165,581 D
2025-11-26 Neal Shana Carol Officer A-Award A Common Stock 6,727 0.00 20,255 D
2025-11-26 Muhsin Bilal Officer A-Award A Common Stock 9,530 0.00 21,751 D
2025-11-26 Mocherla Pavan Kumar Officer A-Award A Common Stock 2,208 0.00 5,055 D
2025-11-26 Goette Roland Officer A-Award A Common Stock 1,906 0.00 16,123 D
2025-11-26 Garrison Michael David Officer A-Award A Common Stock 3,048 0.00 15,503 D
2025-11-26 Feld Michael Officer A-Award A Common Stock 8,829 0.00 17,074 D
2025-11-26 DelOrefice Christopher Officer F-InKind D Common Stock 4,245 0.00 22,982 D
2025-11-26 Byrd Richard Officer A-Award A Common Stock 2,385 0.00 15,568 D
2025-11-07 SCOTT BERTRAM L Director S-Sale D Common Stock 217 176.58 38.3K 35,816 D
2025-11-04 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 168 0.00 11,316 D
2025-11-04 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 34 0.00 1,675 D
2025-10-27 Feld Michael Officer S-Sale D Common Stock 57 186.01 10.6K 8,245 D
2025-09-26 Feld Michael Officer S-Sale D Common Stock 58 181.03 10.5K 8,302 D
2025-09-10 Fraser Claire Director S-Sale D Common Stock 917 187.50 171.9K 22,226 D
2025-09-01 DelOrefice Christopher Officer F-InKind D Common Stock 278 0.00 21,221 D
2025-09-01 Byrd Richard Officer F-InKind D Common Stock 216 0.00 6,736 D
2025-08-22 Feld Michael Officer S-Sale D Common Stock 57 197.99 11.3K 8,360 D
2025-08-20 Feld Michael Officer F-InKind D Common Stock 773 0.00 8,417 D
2025-08-11 HAYES GREGORY Director P-Purchase A Common Stock 5,250 191.57 1.01M 6,046 D
2025-08-08 Fraser Claire Director S-Sale D Common Stock 863 192.30 166.0K 23,143 D
2025-08-07 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 168 0.00 11,089 D
2025-08-07 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 34 0.00 1,632 D
2025-07-18 Garrison Michael David Officer M-Exempt D Stock Appreciation Rights 6,360 147.68 939.2K 0 D
2025-07-02 Muhsin Bilal Officer A-Award A Common Stock 12,221 0.00 12,221 D
2025-06-02 Shan David Officer S-Sale D Common Stock 1,166 171.19 199.6K 4,575 D
2025-05-06 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 145 0.00 10,855 D
2025-05-06 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 29 0.00 1,588 D
2025-04-09 Garrison Michael David Officer S-Sale D Common Stock 479 197.28 94.5K 4,887 D
2025-04-04 Neal Shana Carol Officer F-InKind D Common Stock 1,886 0.00 13,528 D
2025-03-26 HAYES GREGORY Director No securities are beneficially owned 0 0.00 0 D
2025-03-18 Byrd Richard Officer S-Sale D Common Stock 459 230.00 105.6K 6,952 D
2025-03-12 Byrd Richard Officer S-Sale D Common Stock 1,940 224.91 436.3K 7,411 D
2025-03-01 Garrison Michael David Officer F-InKind D Common Stock 178 0.00 5,366 D
2025-02-12 SCOTT BERTRAM L Director S-Sale D Common Stock 700 227.99 159.6K 36,033 D
2025-02-10 Henderson Jeffrey William Director P-Purchase A Common Stock 1,500 233.62 350.4K 8,015 D
2025-02-06 Spikner Pamela L. Officer Common Stock 0 0.00 682 D
2025-02-06 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 222 0.00 10,662 D
2025-02-06 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 121 0.00 1,552 D
2025-01-28 Waldstreicher Joanne Director A-Award A Common Stock 930 0.00 2,270 D
2025-01-28 SCOTT BERTRAM L Director A-Award A Common Stock 930 0.00 36,733 D
2025-01-28 RING TIMOTHY M Director A-Award A Common Stock 930 0.00 57,915 D
2025-01-28 Jones Christopher Ian Montague Director A-Award A Common Stock 930 0.00 22,701 D
2025-01-28 Henderson Jeffrey William Director A-Award A Common Stock 930 0.00 6,515 D
2025-01-28 Fraser Claire Director A-Award A Common Stock 930 0.00 24,006 D
2025-01-28 ECKERT R ANDREW Director A-Award A Common Stock 930 0.00 9,170 D
2025-01-28 Byington Carrie L Director A-Award A Common Stock 930 0.00 3,834 D
2025-01-28 Brown William M Director A-Award A Common Stock 930 0.00 3,486 D
2025-01-28 BURZIK CATHERINE M Director A-Award A Common Stock 930 0.00 14,264 D
2025-01-21 Shan David Officer S-Sale D Common Stock 500 240.00 120.0K 5,741 D
2025-01-21 Neal Shana Carol Officer S-Sale D Common Stock 787 240.00 188.9K 15,414 D
2025-01-17 Garrison Michael David Officer S-Sale D Common Stock 597 236.51 141.2K 5,544 D
2025-01-07 Neal Shana Carol Officer S-Sale D Common Stock 788 235.00 185.2K 16,201 D
2025-01-03 Shan David Officer F-InKind D Common Stock 44 0.00 6,241 D
2024-12-19 Garrison Michael David Officer S-Sale D Common Stock 2,838 223.33 633.8K 6,141 D
2024-12-09 Goette Roland Officer S-Sale D Common Stock 638 219.03 139.7K 14,217 D
2024-12-06 Neal Shana Carol Officer S-Sale D Common Stock 1,000 220.49 220.5K 16,989 D
2024-12-06 Goette Roland Officer M-Exempt D Stock Appreciation Rights 6,339 167.91 1.06M 0 D
2024-12-05 Shan David Officer S-Sale D Common Stock 1,500 220.25 330.4K 6,285 D
2024-11-26 Urbini Massimiliano Officer Stock Appreciation Rights 1,843 238.89 440.3K 0 D
2024-11-26 Shan David Officer A-Award A Common Stock 1,106 0.00 7,909 D
2024-11-26 Roque Vitor Officer Stock Appreciation Rights 1,843 238.89 440.3K 0 D
2024-11-26 Quinn Michelle Officer F-InKind D Common Stock 376 0.00 6,927 D
2024-11-26 Polen Thomas E Jr Officer A-Award A Common Stock 36,585 0.00 123,935 D
2024-11-26 Neal Shana Carol Officer A-Award A Common Stock 2,109 0.00 18,498 D
2024-11-26 Mocherla Pavan Kumar Officer A-Award A Common Stock 180 0.00 2,872 D
2024-11-26 Goette Roland Officer A-Award A Common Stock 2,161 0.00 15,690 D
2024-11-26 Garrison Michael David Officer F-InKind D Common Stock 1,230 0.00 8,979 D
2024-11-26 Feld Michael Officer A-Award A Common Stock 2,553 0.00 9,190 D
2024-11-26 Ezell Antoine C Officer A-Award A Stock Appreciation Rights 5,437 224.25 1.22M 5,437 D
2024-11-26 DelOrefice Christopher Officer F-InKind D Common Stock 5,192 0.00 21,499 D
2024-11-26 Byrd Richard Officer A-Award A Common Stock 2,275 0.00 10,555 D
2024-11-21 Neal Shana Carol Officer F-InKind D Common Stock 32 0.00 16,989 D
2024-11-05 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 128 0.00 10,392 D
2024-11-05 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 128 0.00 1,424 D
2024-09-07 DelOrefice Christopher Officer F-InKind D Common Stock 466 0.00 12,792
2024-09-01 DelOrefice Christopher Officer F-InKind D Common Stock 254 0.00 13,258
2024-09-01 Byrd Richard Officer F-InKind D Common Stock 216 0.00 6,060
2024-08-20 Feld Michael Officer D Common Stock 0 0.00 3
2024-08-14 Goette Roland Officer M-Exempt A Common Stock 5,295 132.54 701.8K 16,603
2024-07-31 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 124 0.00 10,224
2024-07-31 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 124 0.00 1,291
2024-07-01 Spoerel Thomas J Officer F-InKind D Common Stock 48 0.00 1,928
2024-06-10 Spoerel Thomas J Officer S-Sale D Common Stock 300 239.31 71.8K 1,976
2024-05-15 Goette Roland Officer S-Sale D Common Stock 800 235.29 188.2K 13,808
2024-05-13 Goette Roland Officer S-Sale D Common Stock 28 237.90 6.7K 14,608
2024-05-03 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 129 0.00 9,954
2024-05-03 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 129 0.00 1,162
2024-04-30 Garrison Michael David Officer S-Sale D Common Stock 1,715 232.81 399.3K 5,381
2024-04-04 Neal Shana Carol Officer F-InKind D Common Stock 1,921 0.00 16,389
2024-03-14 Spoerel Thomas J Officer S-Sale D Common Stock 282 238.29 67.2K 2,276
2024-03-01 Spoerel Thomas J Officer F-InKind D Common Stock 36 0.00 2,558
2024-03-01 Garrison Michael David Officer F-InKind D Common Stock 178 0.00 7,096
2024-03-01 Ezell Antoine C Officer F-InKind D Common Stock 282 0.00 9,320
2024-02-05 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 126 0.00 9,787
2024-02-05 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 126 0.00 1,029
2024-01-23 Waldstreicher Joanne Director A-Award A Common Stock 900 0.00 1,323
2024-01-23 SCOTT BERTRAM L Director A-Award A Common Stock 900 0.00 35,197
2024-01-23 RING TIMOTHY M Director A-Award A Common Stock 900 0.00 56,890
2024-01-23 Jones Christopher Ian Montague Director A-Award A Common Stock 900 0.00 21,405
2024-01-23 Henderson Jeffrey William Director A-Award A Common Stock 900 0.00 5,568
2024-01-23 Fraser Claire Director A-Award A Common Stock 900 0.00 22,696
2024-01-23 ECKERT R ANDREW Director A-Award A Common Stock 900 0.00 8,124
2024-01-23 Byington Carrie L Director A-Award A Common Stock 900 0.00 2,855
2024-01-23 Brown William M Director A-Award A Common Stock 900 0.00 2,512
2024-01-23 BURZIK CATHERINE M Director A-Award A Common Stock 900 0.00 13,242
2024-01-03 Shan David Officer F-InKind D Common Stock 44 0.00 5,693
2023-12-11 Garrison Michael David Officer S-Sale D Common Stock 1,239 232.46 288.0K 7,274
2023-11-28 Byrd Richard Officer S-Sale D Common Stock 2,156 238.47 514.1K 4,120
2023-11-26 Urbini Massimiliano Officer Stock Appreciation Rights 2,378 238.06 566.1K 0 D
2023-11-26 Spoerel Thomas J Officer A-Award A Common Stock 757 0.00 2,959
2023-11-26 Shan David Officer D Stock Apprciation Rights 5,305 238.06 1.26M 0
2023-11-26 Roque Vitor Officer Stock Appreciation Rights 2,195 238.06 522.5K 0 D
2023-11-26 Quinn Michelle Officer A-Award A Common Stock 909 0.00 5,395
2023-11-26 Polen Thomas E Jr Officer A-Award A Rights to Common Stock Under Deferred Compensation Plan 7,520 238.89 1.80M 70,855
2023-11-26 Neal Shana Carol Officer A-Award A Common Stock 1,659 0.00 18,568
2023-11-26 Mocherla Pavan Kumar Officer A-Award A Stock Appreciation Rights 2,764 238.89 660.3K 2,764
2023-11-26 Hickey David Officer A-Award A Rights to Common Stock Under Deferred Compensation Plan 3,024 238.89 722.4K 12,237
2023-11-26 Goette Roland Officer A-Award A Common Stock 2,608 0.00 18,603
2023-11-26 Garrison Michael David Officer F-InKind D Common Stock 1,646 0.00 8,513
2023-11-26 Ezell Antoine C Officer A-Award A Stock Appreciation Rights 5,298 238.89 1.27M 5,298
2023-11-26 DelOrefice Christopher Officer F-InKind D Common Stock 812 0.00 13,512
2023-11-26 Byrd Richard Officer A-Award A Stock Appreciation Rights 8,061 238.89 1.93M 8,061
2023-11-20 Neal Shana Carol Officer M-Exempt D Rights to Common Stock Under Deferred Compensation Plan 110 0.00 448 D
2023-11-16 Goette Roland Officer M-Exempt A Common Stock 3,544 107.12 379.6K 17,164
2023-11-03 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 118 0.00 9,624
2023-11-03 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 118 0.00 910
2023-09-07 DelOrefice Christopher Officer F-InKind D Common Stock 601 0.00 10,999
2023-09-05 Byrd Richard Officer S-Sale D Common Stock 459 274.48 126.0K 3,444
2023-09-01 DelOrefice Christopher Officer F-InKind D Common Stock 353 0.00 11,600
2023-09-01 Byrd Richard Officer F-InKind D Common Stock 216 0.00 3,903
2023-08-28 Fraser Claire Director S-Sale D Common Stock 848 281.66 238.8K 21,608
2023-08-11 Hickey David Officer S-Sale D Common Stock 2,974 277.85 826.3K 4,199
2023-08-08 Garrison Michael David Officer S-Sale D Common Stock 1,300 277.13 360.3K 5,157
2023-08-02 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 108 0.00 9,441
2023-08-02 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 108 0.00 785
2023-07-24 Waldstreicher Joanne Director A-Award A Common Stock 419 0.00 419
2023-07-01 Spoerel Thomas J Officer A-Award D Common Stock 47 0.00 1,827
2023-05-05 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 118 0.00 9,270
2023-05-05 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 118 0.00 671
2023-05-01 Quinn Michelle Officer F-InKind D Common Stock 99 0.00 3,280
2023-04-04 Neal Shana Carol Officer F-InKind D Common Stock 731 0.00 8,680
2023-03-02 Ezell Antoine C Officer F-InKind D Common Stock 650 0.00 7,187
2023-03-01 Spoerel Thomas J Officer F-InKind D Common Stock 35 0.00 1,874
2023-03-01 Garrison Michael David Officer F-InKind D Common Stock 193 0.00 6,457
2023-03-01 Ezell Antoine C Officer F-InKind D Common Stock 418 0.00 7,837
2023-02-03 Quinn Michelle Officer D Common Stock 0 0.00 3,379
2023-02-03 Byrd Richard Officer S-Sale D Common Stock 1,421 248.60 353.3K 4,119
2023-02-02 Jones Christopher Ian Montague Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 205 0.00 9,086
2023-02-02 Byington Carrie L Director A-Award A Rights to Common Stock Under BD Deferred Compensation Plan 106 0.00 548
2023-01-26 Fraser Claire Director A-Award A Common Stock 848 0.00 22,311
2023-01-24 SCOTT BERTRAM L Director A-Award A Common Stock 848 0.00 33,779
2023-01-24 RING TIMOTHY M Director A-Award A Common Stock 848 0.00 78,830
2023-01-24 LARSEN MARSHALL O Director A-Award A Common Stock 848 0.00 28,919
2023-01-24 Jones Christopher Ian Montague Director A-Award A Common Stock 848 0.00 29,171
2023-01-24 Henderson Jeffrey William Director A-Award A Common Stock 848 0.00 4,653
2023-01-24 ECKERT R ANDREW Director A-Award A Common Stock 848 0.00 6,992
2023-01-24 Byington Carrie L Director A-Award A Common Stock 848 0.00 1,924
2023-01-24 Brown William M Director A-Award A Common Stock 848 0.00 1,586
2023-01-24 BURZIK CATHERINE M Director A-Award A Common Stock 848 0.00 13,425
2023-01-23 Shan David Officer D Common Stock 0 0.00 3,478
2022-12-21 Khichi Samrat S. Officer G-Gift D Common Stock 19 0.00 9,251
2022-12-13 Khichi Samrat S. Officer G-Gift D Common Stock 40 0.00 9,270

Executive team

Top executives
EBIT / Employee
35.6K
Shares Outstanding
362.30M

Executive compensation

Executive compensation (annual)
# Year Executive Salary Bonus Stock award Option award Incentive Other Total % Stock-
based
Filing
1 2025 Thomas E. Polen Chairman, Chief Executive Officer and President 1.40M 9.99M 3.31M 1.85M 578.0K 17.13M 77.67%
2 2025 Christopher J. DelOrefice Executive Vice President and Chief Financial Officer 837.5K 3.14M 1.04M 722.5K 135.8K 5.88M 71.15%
3 2025 Michael C. Feld Executive Vice President, Chief Revenue Officer and President, Life Sciences Segment 775.0K 1.64M 544.1K 533.6K 602.1K 4.10M 53.36%
4 2025 Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments 768.8K 1.64M 544.1K 533.6K 161.0K 3.65M 59.90%
5 2025 Richard E. Byrd Executive Vice President and President, Interventional Segment 756.3K 1.43M 473.1K 592.9K 149.3K 3.40M 55.92%
6 2024 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 1.35M 9.24M 3.99M 2.11M 613.4K 17.31M 76.45%
7 2024 Thomas E. Polen Chairman, Chief Executive Officer and President 1.35M 9.24M 3.99M 2.11M 613.4K 17.31M 76.45%
8 2024 Christopher J. DelOrefice Executive Vice President and Chief Financial Officer 785.4K 2.69M 1.16M 906.4K 85.6K 5.63M 68.42%
9 2024 Michael D. Garrison Executive Vice President and President, Medical Segment 731.3K 1.51M 653.5K 556.2K 168.1K 3.62M 59.82%
10 2024 Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments 731.3K 1.51M 653.5K 556.2K 168.1K 3.62M 59.82%
11 2024 Shana Neal Executive Vice President and Chief People Officer 622.6K 1.34M 579.4K 484.5K 280.3K 3.31M 58.07%
12 2024 Richard E. Byrd Executive Vice President and President, Interventional Segment 681.3K 1.18M 508.2K 648.9K 253.6K 3.27M 51.55%
13 2023 Thomas E. Polen Chairman, Chief Executive Officer and President 1.32M 9.49M 4.04M 1.89M 570.2K 17.31M 78.20%
14 2023 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 1.32M 9.49M 4.04M 1.89M 570.2K 17.31M 78.20%
15 2023 Shana Neal Executive Vice President and Chief People Officer 606.7K 375.0K 3.47M 632.8K 433.8K 369.9K 5.89M 69.67%
16 2023 Christopher J. DelOrefice Executive Vice President and Chief Financial Officer 736.2K 2.53M 1.08M 775.0K 85.5K 5.21M 69.33%
17 2023 Michael D. Garrison Executive Vice President and President, Medical Segment 675.0K 1.28M 547.1K 599.6K 548.2K 3.65M 50.12%
18 2023 Michael D. Garrison Executive Vice President and President, Medical Essentials and BioPharma Systems Segments 675.0K 1.28M 547.1K 599.6K 548.2K 3.65M 50.12%
19 2023 David B. Hickey Executive Vice President and President, Life Sciences Segment 649.3K 1.49M 634.4K 422.5K 151.0K 3.35M 63.46%
20 2022 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 1.28M 8.89M 3.74M 2.49M 313.8K 16.71M 75.57%
21 2022 Christopher J. DelOrefice Executive Vice President and Chief Financial Officer 720.0K 230.0K 2.85M 921.6K 970.6K 147.8K 5.84M 64.61%
22 2022 Alberto Mas Former Executive Vice President and President, Medical Segment 734.1K 300.0K 1.78M 747.7K 891.9K 67.5K 4.52M 55.88%
23 2022 Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel 766.9K 1.61M 676.3K 931.8K 132.2K 4.11M 55.50%
24 2022 David B. Hickey Executive Vice President and President, Life Sciences Segment 620.0K 1.24M 520.3K 765.9K 118.2K 3.26M 53.88%
25 2022 Shana Neal Executive Vice President and Chief People Officer 300.0K 375.0K 1.89M 434.2K 221.0K 3.22M 58.71%
26 2021 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 1.23M 6.23M 4.10M 2.36M 273.7K 14.19M 72.79%
27 2021 Christopher R. Reidy Executive Vice President and Chief Administrative Officer 878.3K 2.02M 1.75M 1.01M 152.3K 5.81M 64.94%
28 2021 Alberto Mas Executive Vice President and President, Medical Segment 713.5K 1.46M 1.22M 848.7K 92.1K 4.34M 61.87%
29 2021 Alberto Mas Former Executive Vice President and President, Medical Segment 713.5K 1.46M 1.22M 848.7K 92.1K 4.34M 61.87%
30 2021 Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel 700.8K 1.01M 883.3K 724.1K 210.9K 3.53M 53.67%
31 2021 Simon D. Campion Executive Vice President and President, Interventional Segment 612.5K 1.08M 848.8K 671.7K 207.2K 3.42M 56.42%
32 2021 Christopher J. DelOrefice Executive Vice President and Chief Financial Officer 60.0K 450.0K 1.10M 1.6K 1.61M 68.16%
33 2020 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 951.7K 5.64M 3.75M 1.09M 238.9K 11.67M 80.43%
34 2020 Thomas E. Polen President and Chief Executive Officer 951.7K 5.64M 3.75M 1.09M 238.9K 11.67M 80.43%
35 2020 Christopher R. Reidy Executive Vice President and Chief Administrative Officer 775.9K 2.04M 1.36M 582.0K 165.8K 4.92M 69.02%
36 2020 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 775.9K 2.04M 1.36M 582.0K 165.8K 4.92M 69.02%
37 2020 Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel 627.0K 1.05M 926.7K 616.5K 455.4K 261.1K 3.94M 39.19%
38 2020 Alberto Mas Executive Vice President and President, Medical Segment 665.4K 1.42M 945.2K 446.5K 239.1K 3.72M 63.66%
39 2020 Alberto Mas Former Executive Vice President and President, Medical Segment 665.4K 1.42M 945.2K 446.5K 239.1K 3.72M 63.66%
40 2020 Alberto Mas Executive Vice President and President, Medical 665.4K 1.42M 945.2K 446.5K 239.1K 3.72M 63.66%
41 2020 Patrick K. Kaltenbach Executive Vice President, and President, Life 636.0K 750.0K 1.33M 884.6K 490.8K 70.7K 3.67M 60.32%
42 2020 Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs 627.0K 1.05M 926.7K 616.5K 455.4K 261.1K 3.48M 44.31%
43 2020 Vincent A. Forlenza Chairman of the Board 1.09M 1.35M 775.8K 3.21M 0.00%
44 2019 Vincent A. Forlenza Chairman of the Board 1.28M 7.27M 4.80M 1.95M 724.6K 16.01M 75.34%
45 2019 Patrick K. Kaltenbach Executive Vice President, and President, Life 664.6K 750.0K 4.14M 878.8K 562.4K 53.4K 7.05M 71.18%
46 2019 Thomas E. Polen Chairman of the Board, Chief Executive Officer and President 900.0K 2.35M 1.55M 990.0K 237.6K 6.03M 64.72%
47 2019 Thomas E. Polen President and Chief Executive Officer 900.0K 2.35M 1.55M 990.0K 237.6K 6.03M 64.72%
48 2019 Christopher R. Reidy Executive Vice President and Chief Administrative Officer 853.9K 1.73M 1.14M 850.0K 163.4K 4.74M 60.63%
49 2019 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 853.9K 1.73M 1.14M 850.0K 163.4K 4.74M 60.63%
50 2019 Alberto Mas Executive Vice President and President, Medical Segment 695.3K 1.42M 939.0K 588.3K 597.4K 4.24M 55.66%
51 2019 Alberto Mas Executive Vice President and President, Medical 695.3K 1.42M 939.0K 588.3K 597.4K 4.24M 55.66%
52 2019 Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs 631.0K 1.05M 835.3K 551.2K 607.2K 275.9K 3.95M 35.08%
53 2019 Samrat S. Khichi Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs & General Counsel 631.0K 1.05M 835.3K 551.2K 607.2K 275.9K 3.95M 35.08%
54 2018 Vincent A. Forlenza Chairman and Chief Executive Officer 1.19M 6.69M 4.42M 1.98M 684.7K 14.97M 74.25%
55 2018 Vincent A. Forlenza Chairman of the Board 1.19M 6.69M 4.42M 1.98M 684.7K 14.97M 74.25%
56 2018 Thomas E. Polen President and Chief Executive Officer 849.8K 2.23M 1.47M 1.13M 140.7K 5.83M 63.58%
57 2018 Thomas E. Polen President and Chief Operating Officer 849.8K 2.23M 1.47M 1.13M 140.7K 5.83M 63.58%
58 2018 Patrick K. Kaltenbach Executive Vice President, and President, Life 216.7K 2.00M 1.66M 1.12M 205.7K 18.6K 5.23M 53.31%
59 2018 Patrick K. Kaltenbach Executive Vice President, and President, Life Sciences 216.7K 2.00M 1.66M 1.12M 205.7K 8.8K 5.22M 53.41%
60 2018 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 818.2K 1.99M 1.32M 902.8K 149.6K 5.18M 63.88%
61 2018 Samrat S. Khichi Executive Vice President and General Counsel 450.0K 1.05M 1.05M 692.9K 371.3K 20.2K 3.75M 46.40%
62 2018 Sciences Segment Samrat S. Khichi Executive Vice President and General Counsel, Public Policy and Regulatory Affairs 450.0K 1.05M 1.05M 692.9K 371.3K 115.0K 3.73M 46.68%
63 2017 Vincent A. Forlenza Chairman and Chief Executive Officer 1.15M 5.64M 3.79M 1.80M 668.7K 13.06M 72.26%
64 2017 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 778.2K 1.64M 1.10M 950.0K 149.8K 4.62M 59.39%
65 2017 Thomas E. Polen President and Chief Operating Officer 761.4K 1.49M 1.00M 875.0K 119.7K 4.25M 58.71%
66 2017 Thomas E. Polen President 761.4K 1.49M 1.00M 875.0K 119.7K 4.25M 58.71%
67 2017 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 686.8K 1.04M 702.7K 603.3K 122.2K 3.16M 55.31%
68 2017 Alexandre Conroy President, Worldwide Medication and Procedural Solutions 576.2K 940.5K 632.5K 583.5K 240.4K 2.97M 52.91%
69 2016 Vincent A. Forlenza Chairman and Chief Executive Officer 1.11M 5.72M 4.57M 2.00M 530.8K 13.93M 73.90%
70 2016 Vincent A. Forlenza Chairman, Chief Executive Officer and President 1.11M 5.72M 4.57M 2.00M 530.8K 13.93M 73.90%
71 2016 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 746.6K 1.53M 1.22M 886.3K 144.9K 4.52M 60.71%
72 2016 William A. Kozy. Former Executive Vice President and Chief Operating Officer 386.1K 1.72M 1.37M 519.7K 436.2K 4.43M 69.71%
73 2016 Thomas E. Polen Executive Vice President and President, Medical Segment 651.0K 953.7K 762.1K 748.6K 145.4K 3.26M 52.62%
74 2016 Thomas E. Polen President and Chief Operating Officer 651.0K 953.7K 762.1K 748.6K 145.4K 3.26M 52.62%
75 2016 Thomas E. Polen President 651.0K 953.7K 762.1K 748.6K 145.4K 3.26M 52.62%
76 2016 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 664.4K 953.7K 762.1K 617.9K 126.7K 3.12M 54.91%
77 2016 Alexandre Conroy Executive Vice President and President, Europe, EMA and Americas 530.3K 834.6K 666.9K 486.9K 236.6K 2.76M 54.49%
78 2016 Alexandre Conroy President, Worldwide Medication and Procedural Solutions 530.3K 834.6K 666.9K 486.9K 236.6K 2.76M 54.49%
79 2015 Vincent A. Forlenza Chairman, Chief Executive Officer and President 1.05M 5.38M 1.66M 44.8K 11.71M 45.96%
80 2015 Vincent A. Forlenza Chairman and Chief Executive Officer 1.05M 5.38M 3.58M 1.66M 44.8K 11.71M 76.50%
81 2015 Vincent A. Forlenza Chairman, Chief Executive Officer and President 1.05M 5.38M 3.58M 1.66M 44.8K 11.71M 76.50%
82 2015 William A. Kozy Executive Vice President and Chief Operating Officer 749.8K 1.75M 1.00M 49.5K 5.17M 33.84%
83 2015 William A. Kozy. Former Executive Vice President and Chief Operating Officer 749.8K 1.75M 1.16M 1.00M 509.4K 5.17M 56.33%
84 2015 Christopher R. Reidy Executive Vice President, Chief Financial Officer and 713.5K 1.36M 712.8K 48.7K 3.82M 35.65%
85 2015 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 713.5K 1.36M 904.9K 712.8K 126.3K 3.82M 59.35%
86 2015 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 637.3K 972.7K 585.5K 43.7K 2.95M 32.95%
87 2015 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 637.3K 972.7K 646.4K 585.5K 110.4K 2.95M 54.84%
88 2015 Jeffrey S. Sherman Executive Vice President and General Counsel 560.3K 875.5K 458.2K 48.7K 2.65M 33.08%
89 2014 Vincent A. Forlenza Chairman, Chief Executive Officer and President 985.0K 4.65M 3.15M 1.40M 791.6K 10.98M 71.08%
90 2014 Vincent A. Forlenza Chairman, Chief Executive Officer and President 985.0K 4.65M 1.40M 35.7K 10.98M 42.37%
91 2014 William A. Kozy Executive Vice President and Chief Operating Officer 721.0K 1.86M 736.1K 40.4K 5.07M 36.71%
92 2014 William A. Kozy. Former Executive Vice President and Chief Operating Officer 721.0K 1.86M 1.26M 736.1K 490.5K 5.07M 61.59%
93 2014 Christopher R. Reidy Executive Vice President, Chief Financial Officer and Chief Administrative Officer 690.2K 1.24M 841.0K 663.9K 63.6K 3.50M 59.49%
94 2014 Christopher R. Reidy Chief Financial Officer and Executive Vice President of Administration 690.2K 1.24M 841.0K 663.9K 21.5K 3.50M 59.49%
95 2014 Christopher R. Reidy Executive Vice President, Chief Financial Officer and 690.2K 1.24M 663.9K 21.5K 3.50M 35.46%
96 2014 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 615.8K 285.0K 806.6K 531.6K 11.7K 2.84M 28.39%
97 2014 Jeffrey S. Sherman Executive Vice President and General Counsel 540.8K 806.6K 409.0K 39.8K 2.45M 32.96%
98 2014 Ellen R. Strahlman, M.D. Executive Vice President, Research and Development and Chief Medical Officer 540.8K 806.6K 546.7K 409.0K 144.2K 2.45M 55.30%
99 2014 Jeffrey S. Sherman Senior Vice President and General Counsel 540.8K 806.6K 546.7K 409.0K 39.8K 2.45M 55.30%
100 2013 Vincent A. Forlenza Chairman, Chief Executive Officer and President 930.0K 3.76M 1.23M 36.0K 9.18M 40.92%
101 2013 William A. Kozy Executive Vice President and Chief Operating Officer 690.0K 1.84M 865.1K 39.7K 5.38M 34.27%
102 2013 Jeffrey S. Sherman Senior Vice President and General Counsel 516.3K 903.2K 588.6K 530.9K 39.0K 3.18M 46.88%
103 2013 Jeffrey S. Sherman Executive Vice President and General Counsel 516.3K 903.2K 530.9K 39.0K 3.18M 28.38%
104 2013 Christopher R. Reidy Executive Vice President, Chief Financial Officer and 144.2K 131.2K 4.6K 286.4K 0.00%
105 2013 Christopher R. Reidy Chief Financial Officer and Executive Vice President of Administration 144.2K 131.2K 4.6K 286.4K 0.00%
106 2012 Vincent A. Forlenza Chairman, Chief Executive Officer and President 900.0K 3.44M 2.29M 1.08M 41.8K 9.42M 60.88%
107 2012 William A. Kozy Executive Vice President and Chief Operating Officer 643.3K 1.37M 912.3K 724.5K 44.6K 4.81M 47.44%
108 2012 Jeffrey S. Sherman Senior Vice President and General Counsel 486.3K 839.9K 559.4K 444.3K 34.3K 2.48M 56.41%
109 2009 Edward J. Ludwig Chairman and Chief Executive Officer 1.07M 2.00M 1.60M 1.50M 33.1K 9.12M 39.46%
110 2009 Vincent A. Forlenza President 622.5K 627.9K 556.5K 625.0K 36.2K 3.58M 33.12%
111 2009 William A. Kozy Executive Vice President 567.2K 479.2K 385.4K 470.0K 35.4K 3.15M 27.44%
112 2009 John R. Considine Vice Chairman 692.9K 597.3K 463.3K 600.0K 32.5K 2.98M 35.58%
113 2009 David V. Elkins Executive Vice President and Chief Financial Officer 413.5K 220.0K 91.0K 350.0K 78.4K 1.17M 7.80%
114 2008 Edward J. Ludwig Chairman and Chief Executive Officer 1.06M 3.00M 1.92M 1.53M 14.3K 7.52M 65.40%
115 2008 John R. Considine Vice Chairman 667.2K 955.7K 599.5K 675.0K 11.1K 3.13M 49.65%
116 2008 Vincent A. Forlenza President 538.7K 975.8K 838.6K 625.0K 39.6K 3.02M 60.13%
117 2008 William A. Kozy Executive Vice President 538.7K 725.8K 465.4K 470.0K 14.0K 2.21M 53.81%
118 2007 Edward J. Ludwig Chairman and Chief Executive Officer 1.03M 2.96M 2.19M 1.40M 19.2K 8.05M 64.01%
119 2007 John R. Considine Vice Chairman 644.0K 1.03M 670.0K 7.3K 3.25M 31.54%
120 2007 Vincent A. Forlenza President 510.2K 847.4K 585.0K 7.3K 2.74M 30.90%
121 2007 William A. Kozy Executive Vice President 509.2K 855.5K 425.0K 7.5K 2.67M 32.10%
122 2006 Edward J. Ludwig Chairman, President and Chief Executive Officer 1.02M 1.15M 990.9K 86.8K 7.7K 3.17M 34.00%
123 2006 John R. Considine Senior Executive Vice President and Chief 620.7K 500.0K 321.3K 28.2K 7.3K 1.45M 24.12%
124 2006 Gary M. Cohen Executive Vice President 509.7K 355.0K 243.7K 21.4K 7.1K 1.12M 23.76%
125 2006 Vincent A. Forlenza Executive Vice President 476.4K 340.0K 241.0K 21.1K 7.1K 1.06M 24.62%
126 2006 William A. Kozy Executive Vice President 472.7K 340.0K 241.0K 21.1K 7.1K 1.06M 24.71%
127 2005 Edward J. Ludwig Chairman, President and Chief Executive Officer 978.6K 1.56M 804.0K 76.4K 7.5K 3.35M 26.27%
128 2005 John R. Considine Senior Executive Vice President and Chief 594.9K 650.0K 321.6K 30.6K 7.0K 1.57M 22.38%
129 2005 Gary M. Cohen Executive Vice President 488.0K 500.0K 243.9K 23.2K 6.9K 1.24M 21.56%
130 2005 Vincent A. Forlenza Executive Vice President 453.4K 450.0K 241.2K 22.9K 6.8K 1.15M 22.94%
131 2005 William A. Kozy Executive Vice President 449.9K 450.0K 241.2K 22.9K 6.8K 1.15M 23.01%
132 2004 Edward J. Ludwig Chairman, President and Chief Executive Officer 933.7K 1.20M 537.8K 99.0K 7.3K 2.68M 23.77%
133 2004 John R. Considine Senior Executive Vice President and Chief 575.0K 480.0K 217.4K 40.0K 6.8K 1.28M 20.12%
134 2004 Gary M. Cohen Executive Vice President 472.5K 345.0K 163.0K 6.7K 987.2K 16.51%
135 2004 Vincent A. Forlenza Executive Vice President 436.2K 330.0K 141.3K 6.7K 914.2K 15.46%
136 2004 William A. Kozy Executive Vice President 428.7K 330.0K 141.3K 6.7K 906.7K 15.58%
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2025-12-18 DEFA14A
2025-12-18 DEF 14A

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-07 S-8
2026-05-07 S-8
2026-05-07 8-K/A
2026-05-07 8-K
2026-05-07 10-Q
2026-04-29 SC 13G
2026-04-29 SC 13G
2026-04-29 8-K
2026-04-28 4
2026-04-27 144

Executive team

NameTitleCompensationGender
Thomas E. Polen Jr. President, Chief Executive Officer & Chairman 4M male
Michael C. Feld Executive VP & Chief Revenue Officer 2M male
Richard Byrd Executive Vice President & President of Interventional Segment 1M male
Michael Garrison Executive VP & President of Medical Segment and BioPharma Systems Segments 1M male
Pamela L. Spikner Senior Vice President, Chief Accounting Officer & Controller female
Shawn C. Bevec Senior Vice President of Investor Relations male
Claudia Curtis Senior Vice President, Chief Ethics & Compliance Officer female
Vitor Roque Senior VP of Business Finance & Interim CFO male
Denise Fleming Executive Vice President of Technology & Global Services and Chief Information Officer female
Elizabeth McCombs Executive Vice President & Chief Technology Officer female
Joseph Smith Senior Vice President & Chief Scientific Officer
ESG Rating
B+
MEDICAL - INSTRUMENTS & SUPPLIES
2003
E (Environmental)
75.5 / 64.7
Company / Sector avg.
S (Social)
64.8 / 70.0
Company / Sector avg.
G (Governance)
62.0 / 67.5
Company / Sector avg.
ESG Total
67.4 / 67.4
Company / Sector avg.
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2024-02-15 2024-03-15 Shelley Moore Capito WV Spouse Sale (Full) $1,001 - $15,000
2021-10-18 2021-11-10 Tommy Tuberville AL Joint Sale (Full) $15,001 - $50,000
2018-04-24 2018-05-14 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2018-04-05 2018-05-14 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2016-04-19 2016-05-04 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2026-03-17 2026-04-06 Kevin Hern OK01 Joint Sale $15,001 - $50,000
2025-09-29 2025-10-03 Ro Khanna CA17 Purchase $1,001 - $15,000
2025-06-24 2025-08-13 Lisa McClain MI09 Spouse Sale (Full) $1,001 - $15,000
2025-06-17 2025-08-13 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000
2025-05-15 2025-06-10 Rob Bresnahan PA08 Purchase $1,001 - $15,000
2025-05-13 2025-06-18 Thomas H. Kean NJ07 Purchase $1,001 - $15,000
2025-04-08 2025-04-29 Rob Bresnahan PA08 Sale $1,001 - $15,000
2025-03-05 2025-04-14 Jefferson Shreve IN06 Sale $15,001 - $50,000
2024-09-11 2024-09-25 William R. Keating MA09 Sale $1,001 - $15,000
2024-09-09 2024-10-08 Ro Khanna CA17 Spouse Sale $1,001 - $15,000
2024-09-04 2024-09-06 John James MI10 Sale (Full) $1,001 - $15,000
2024-05-24 2024-06-18 Thomas H. Kean NJ07 Purchase $1,001 - $15,000
2024-03-25 2024-04-05 Ro Khanna CA17 Purchase $1,001 - $15,000
2024-03-21 2024-04-05 Ro Khanna CA17 Purchase $1,001 - $15,000
2024-02-13 2024-03-06 Ro Khanna CA17 Spouse Purchase $1,001 - $15,000
2024-01-11 2024-02-20 Thomas H. Kean NJ07 Self Purchase $1,001 - $15,000
2024-01-10 2024-02-05 Ro Khanna CA17 Sale $1,001 - $15,000
2024-01-03 2024-02-05 Ro Khanna CA17 Spouse Purchase $1,001 - $15,000
2023-11-10 2024-09-02 John James MI10 Purchase $1,001 - $15,000
2023-10-31 2023-11-08 Ro Khanna CA17 Spouse Sale $15,001 - $50,000
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits